Viread
Drug
Gilead Sciences Inc
Total Payments
$3.6M
Transactions
349
Doctors
42
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $26,085 | 3 | 0 |
| 2023 | $3,157 | 1 | 0 |
| 2022 | $213,568 | 18 | 11 |
| 2021 | $320,727 | 8 | 1 |
| 2020 | $39,607 | 19 | 1 |
| 2019 | $447,099 | 87 | 15 |
| 2018 | $375,054 | 85 | 10 |
| 2017 | $2.1M | 128 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 292 | 99.8% |
| Consulting Fee | $4,550 | 5 | 0.1% |
| Food and Beverage | $3,817 | 48 | 0.1% |
| Travel and Lodging | $283.37 | 2 | 0.0% |
| Education | $39.98 | 2 | 0.0% |
Payments by Type
Research
$3.6M
292 transactions
General
$8,690
57 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Trends in demographics and co-morbidities of patients with Study Title chronic hepatitis B in the US | Gilead Sciences Inc | $498,790 | 0 |
| A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection | Gilead Sciences, Inc. | $398,334 | 0 |
| Effect of antiviral therapy on hepatocellular carcinoma incidence in patients with chronic hepatitis B | Gilead Sciences Inc | $385,515 | 0 |
| Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Mother to Child Transmission of Hepatitis B Virus: A Multi-Center, Prospective, Randomized, Open-Label Study | Gilead Sciences Inc | $315,915 | 0 |
| Leukapheresis on Adult Subjects with HIV-1 to Obtain Leukocytes for Testing of Virus Eradication Strategies | Gilead Sciences, Inc. | $278,966 | 0 |
| Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Transplant (OLT) List | Gilead Sciences Inc | $251,568 | 0 |
| Risk of Hepatocellular Carcinoma (HCC) among US Veterans with Chronic Hepatitis B infection receiving Tenofovir or Entecavir | Gilead Sciences, Inc. | $203,819 | 0 |
| Chronic hepatitis B virus clinical epidemiology in a representative sample of Zambian adults | Gilead Sciences, Inc. | $190,785 | 0 |
| Chronic hepatitis B virus clinical epidemiology in a representative sample of Zambian adults | Gilead Sciences Inc | $145,141 | 0 |
| A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection | Gilead Sciences Inc | $139,960 | 0 |
| Leukapheresis on Adult Subjects with HIV-1 to Obtain Leukocytes for Testing of Virus Eradication Strategies | Gilead Sciences Inc | $136,588 | 0 |
| Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of SMARTT | Gilead Sciences, Inc. | $125,000 | 0 |
| Age-Dependent Decline in Renal Function in HBV Patients Receiving Tenofovir Disoproxil Fumarate | Gilead Sciences Inc | $108,675 | 0 |
| Telomere length, telomerase activity, and age-related diseases among HIV-infected individuals on ART | Gilead Sciences, Inc. | $102,360 | 0 |
| Prevalence of HBV Among the Armenian Population in Glendale California | Gilead Sciences Inc | $72,915 | 0 |
| Reducing Liver Cancer Risk by increasing Hepatitis B screening for US Africans | Gilead Sciences Inc | $32,089 | 0 |
| Racial Disparity in Hepatitis B Treatment Responses to Anti-virals: A Proposal to Gather Data Comparing African Americans vs Non African Americans | Gilead Sciences, Inc. | $26,941 | 0 |
| Identification of Agents That Activate HIV-1 Expression in Resting Memory CD4+ Cells Obtained from HIV-Infected Individuals Receiving Suppressive Antiretroviral Therapy | Gilead Sciences, Inc. | $20,700 | 0 |
| A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B | Gilead Sciences Inc | $20,500 | 0 |
| Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Transplant (OLT) List | Gilead Sciences, Inc. | $16,946 | 0 |
Top Doctors Receiving Payments for Viread
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Carol Brosgart | — | Berkeley, CA | $3.6M | 295 |
| , MD | Pediatric Gastroenterology | Boston, MA | $4,550 | 5 |
| , M.D | Psychiatry | Baltimore, MD | $234.69 | 2 |
| , M.D | Infectious Disease | San Francisco, CA | $223.44 | 2 |
| , M.D | Family Medicine | Avondale, AZ | $180.00 | 1 |
| , MD | Infectious Disease | Omaha, NE | $172.12 | 2 |
| , M.D | Emergency Medicine | Bangor, ME | $168.26 | 3 |
| , M.D | Geriatric Medicine | Princeton Junction, NJ | $130.90 | 1 |
| , M.D | Internal Medicine | Towson, MD | $128.03 | 1 |
| , MD | Allergy & Immunology | Washington, DC | $117.49 | 1 |
| , MD | Infectious Disease | San Francisco, CA | $116.95 | 1 |
| , M.D | Internal Medicine | Daly City, CA | $116.95 | 1 |
| , PA-C | Physician Assistant | San Francisco, CA | $116.95 | 1 |
| , PH.D., M.D | Internal Medicine | San Francisco, CA | $116.95 | 1 |
| , M.D | Infectious Disease | Houston, TX | $110.12 | 1 |
| , M.D | Clinical Pharmacology | Baltimore, MD | $109.42 | 2 |
| , M.D | Gastroenterology | Bowie, MD | $106.67 | 1 |
| Lance Sterman | — | East Windsor, NJ | $106.49 | 1 |
| , MD | Internal Medicine | Stanford, CA | $106.49 | 1 |
| , M.D | Family Medicine | San Francisco, CA | $106.48 | 1 |
| , MD | Internal Medicine | San Francisco, CA | $106.48 | 1 |
| , MD | Internal Medicine | San Francisco, CA | $106.48 | 1 |
| , MD | Infectious Disease | Fort Pierce, FL | $103.37 | 1 |
| , M.D | Gastroenterology | San Jose, CA | $98.27 | 1 |
| , M.B.B.S,, M.P.H | Student in an Organized Health Care Education/Training Program | San Jose, CA | $98.27 | 1 |
Ad
Manufacturing Companies
- Gilead Sciences Inc $2.1M
- Gilead Sciences, Inc. $1.4M
Product Information
- Type Drug
- Total Payments $3.6M
- Total Doctors 42
- Transactions 349
About Viread
Viread is a drug associated with $3.6M in payments to 42 healthcare providers, recorded across 349 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $26,085 was paid across 3 transactions to 0 doctors.
The most common payment nature for Viread is "Unspecified" ($3.6M, 99.8% of total).
Viread is associated with 20 research studies, including "Trends in demographics and co-morbidities of patients with Study Title chronic hepatitis B in the US" ($498,790).